BEIJING — Chinese pharmaceutical firm Sinovac Biotech has secured half a billion dollars in extra funding to produce its COVID-19 vaccine, it said Monday, as the country races to roll out a jab for general use.
Beijing has largely brought the virus under control, with only 281 active cases still receiving treatment, according to official figures.
But it has promised to make its vaccines available as a “global public good” as it seeks to counter global criticism for its early handling of the pandemic.
Sino Biopharmaceutical Limited, a Hong Kong-listed medical research firm, said Monday that it will invest $515 million for the development and production of CoronaVac, one of Sino…
Keep on reading: Chinese COVID-19 vaccine maker gets $500M funding boost